- Home
- ASTH vs IDYA Comparison
ASTH vs IDYA Comparison
Compare ASTH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- IDYA
- Stock Information
- Founded
- ASTH 1994
- IDYA 2015
- Country
- ASTH United States
- IDYA United States
- Employees
- ASTH N/A
- IDYA N/A
- Industry
- ASTH Professional Services
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- ASTH Consumer Discretionary
- IDYA Health Care
- Exchange
- ASTH Nasdaq
- IDYA Nasdaq
- Market Cap
- ASTH 1.7B
- IDYA 2.0B
- IPO Year
- ASTH N/A
- IDYA 2019
- Fundamental
- Price
- ASTH $24.00
- IDYA $21.67
- Analyst Decision
- ASTH Strong Buy
- IDYA Strong Buy
- Analyst Count
- ASTH 8
- IDYA 12
- Target Price
- ASTH $53.29
- IDYA $54.27
- AVG Volume (30 Days)
- ASTH 220.5K
- IDYA 1.2M
- Earning Date
- ASTH 08-06-2025
- IDYA 08-05-2025
- Dividend Yield
- ASTH N/A
- IDYA N/A
- EPS Growth
- ASTH N/A
- IDYA N/A
- EPS
- ASTH 0.73
- IDYA N/A
- Revenue
- ASTH $2,250,574,000.00
- IDYA $7,000,000.00
- Revenue This Year
- ASTH $34.97
- IDYA $101.20
- Revenue Next Year
- ASTH $21.52
- IDYA $286.70
- P/E Ratio
- ASTH $32.84
- IDYA N/A
- Revenue Growth
- ASTH 54.81
- IDYA N/A
- 52 Week Low
- ASTH $23.12
- IDYA $13.45
- 52 Week High
- ASTH $63.20
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- ASTH 34.33
- IDYA 58.21
- Support Level
- ASTH $24.76
- IDYA $21.09
- Resistance Level
- ASTH $26.41
- IDYA $22.50
- Average True Range (ATR)
- ASTH 0.93
- IDYA 0.97
- MACD
- ASTH 0.07
- IDYA -0.04
- Stochastic Oscillator
- ASTH 5.06
- IDYA 56.44
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.